Kelun Biotech, a subsidiary of Shenzhen-listed Kelun Pharmaceutical, has secured over 500 million yuan ($77 million) in fresh funding led by CMC-SDIC Capital, a fund co-launched by state-backed China Merchants Capital and SDIC, the lead investor announced on Thursday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
